NanoHybrids’ research and development program explores the application of nanoparticle contrast agents and other nanotechnology-based approaches to diagnose and treat various disease conditions. Our initial technology platform focuses on designing and synthesizing molecularly sensitive contrast agents to be used as imaging agents for oncological applications.
Recent research topics include:
- Using gold nanospheres and nanorods targeted to breast cancer with directional antibody conjugation - funded by a 5-year academic industrial partnership (R01) grant through the National Institutes of Health
- Development of a novel photoacoustic contrast agent - funded by a Small Business Innovative Research (SBIR, phase I) grant from the National Institutes of Health
- Molecularly Targeted Liposomes for Detection of Macrophages in High Risk Artherosclerotic Plaque - funded by a Small Business Innovative Research (SBIR, phase I) contract grant from the National Heart, Lung and Blood Institute
Please contact us at firstname.lastname@example.org to discuss potential collaborations, distribution agreements and strategic partnerships.